In the context of potential further clinical development of S1P signaling inhibition for ccRCC therapy, it is important to note that FTY720 is a well-tolerated orally available drug that is FDA approved and chronically administered to treat multiple sclerosis patients. The gene discussed is MBTPS1; the disease is nonpapillary renal cell carcinoma.